Invasive Fungal Infections in Renal Transplant Recipients: Epidemiology and Risk Factors
Tóm tắt
Invasive fungal infections are a major cause of morbidity and mortality among renal transplant recipients.
The aim of this study was to investigate the frequency and risk factors for fungal infections in renal transplant recipients. We retrospectively evaluated all kidney transplant recipients at our center from December 1988 to June 2010 for the epidemiology, spectrum, risk factors, and mortality of invasive fungal infections.
In 32 patients (10.30 %), at least one fungal infection developed after the transplantation. The most common pathogens causing fungal infections in our patients were Candida spp. and Aspergillus spp. The independent risk factors associated with invasive fungal infection episodes were antibiotic treatment within the last 3 months (OR 15.88, 95 % CI 3.90–64.73, p < 0.001), cytomegalovirus infection (OR 18.54, 95 % CI 9.01–38.17, p < 0.001), and the presence of diabetes mellitus (OR 6.01, 95 % CI 2.95–12.25, p < 0.001). Mortality was significantly higher among patients with fungal infections than among other patients (53.10 and 17.80 %, respectively; p < 0.001). It is difficult to diagnose and treat fungal infections early, and it can be useful to determine independent risk factors in order to identify and treat high-risk patients.
Tài liệu tham khảo
Ersoy A, Yıldız A. Böbrek Transplantasyonunda Viral Olmayan Enfeksiyöz Hastalıklarda Medikal Tedavi. Türkiye Klinikleri J Nephrol (Special Topics). 2010;3:55–62.
Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis. 2000;31:545–53.
Badiee P, Alborzi A. Invasive fungal infections in renal transplant recipients. Exp Clin Transpl. 2011;9:355–62.
Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transpl. 2006;20:401–9.
Altiparmak MR, Apaydin S, Trablus S, et al. Systemic fungal infections after renal transplantation. Scand J Infect Dis. 2002;34:284–8.
Veroux M, Giuffrida G, Corona D, et al. Infective complications in renal allograft recipients: epidemiology and outcome. Transpl Proc. 2008;40:1873–6.
De Pauw B, Walsh TJ, Donnelly JP, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.
Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transpl. 2005;5:218–27.
Patel R. Infections in recipients of kidney transplants. Infect Dis Clin N Am. 2001;15:901–51.
Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis. 2010;50:1101–11.
Abbott KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis. 2001;3:203–11.
Einollahi B, Lessan-Pezeshki M, Pourfarziani V, et al. Invasive fungal infections following renal transplantation: a review of 2410 recipients. Ann Transpl. 2008;13:55–8.
Chen G, Zhang Z, Gu J, et al. Incidence and Risk Factors For Pulmonary Mycosis in Kidney Transplantation. Transplant Proc. 2010;42:4094–8.
Lecompte T, Garzoni C, Mueller N, et al. Fungal infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. 52nd ICAAC, 9–12 Sep 2012, T-343, San Francisco.
Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case–control study to assess risks for disease and outcome. J Infect Dis. 2009;200:1002–11.
Blankenship JR, Wormley FL, Boyce MK, et al. Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot Cell. 2003;2:422–30.
Odom A, Muir S, Lim E, et al. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 1997;16:2576–89.
Steinbach W, Cramer RA, Perfect BZ, et al. Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell. 2006;5:1091–103.
Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis. 2007;195:756–64.
Zhang XD, HU XP, Yin H, et al. Aspergillus pneumoniae in renal transplant recipients. Chin Med J. 2008;128:791–4.
Mason KL, Downward JRE, Mason KD, et al. Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy. Infect Immun. 2012;80:3371–80.
Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014;10:95–105.
Roman A, Manito N, Campistol JM, et al. The impact of the prevention strategies on the direct effects of CMV infection in solid organ transplant recipients. Transpl Rev. 2014;28:84–91.
Rajagopalan S. Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis. 2005;40:990–6.
Chugh KS, Sakhuja V, Jain S, et al. High mortality in systemic fungal infections following renal transplantation in third-world countries. Nephrol Dial Transpl. 1993;8:168.
Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality: systematic review of the literature. Clin Infect Dis. 2001;32:358.
Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine. 1999;78:123.
Rosenhagen M, Feldhues R, Schmidt J, et al. A risk profile for invasive aspergillosis in liver transplant recipients. Infection. 2009;37:313–9.
Baddley JW, Andes DR, Marr KA, et al. Factors associated with in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010;50:1559–67.
Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol. 2004;126:852–60.
Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest. 2010;138:817–24.
Tabarsi P, Soraghi A, Marjani M, et al. Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid organ transplant recipients. Exp Clin Transpl. 2012;10:278–81.
Bitar D, Cauteren DV, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis. 2009;15(9):1395–401.
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.
Einollahi B, Lessan-Pezeshki M, Aslani J, et al. Two decades of experience in mucormycosis after kidney transplantation. Ann Transpl. 2011;16:44–8.